CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel

Guideline26 August 2017

JOURNAL:European Heart Journal Article Link

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery

M.Valgimigli, H. Bueno, R. A. Byrne et al Keywords: Myocardial DiseaseAcute Coronary Syndromes (ACS)Cardiovascular Pharmacology and Pharmacotherapy

Full Text PDF